Scholar Rock (NASDAQ:SRRK) Insider Akshay Vaishnaw Sells 12,246 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the sale, the insider directly owned 630,542 shares of the company’s stock, valued at approximately $31,255,966.94. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

SRRK stock opened at $47.80 on Tuesday. The business has a 50 day moving average price of $46.16 and a 200 day moving average price of $42.12. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of -13.94 and a beta of 0.68. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $51.63. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period in the previous year, the firm posted ($0.64) EPS. Equities research analysts anticipate that Scholar Rock Holding Corporation will post -3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRRK has been the subject of a number of research reports. Wedbush upped their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. Citigroup increased their price objective on Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. JPMorgan Chase & Co. increased their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 16th. Barclays raised their price objective on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $55.40.

Institutional Trading of Scholar Rock

Institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. boosted its holdings in Scholar Rock by 1.5% in the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock worth $927,000 after acquiring an additional 286 shares during the period. E. Ohman J or Asset Management AB boosted its stake in Scholar Rock by 35.2% during the 1st quarter. E. Ohman J or Asset Management AB now owns 22,136 shares of the company’s stock valued at $1,088,000 after acquiring an additional 5,762 shares during the last quarter. Invesco Ltd. lifted its holdings in Scholar Rock by 21.0% during the 4th quarter. Invesco Ltd. now owns 82,462 shares of the company’s stock worth $3,632,000 after buying an additional 14,291 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Scholar Rock in the 4th quarter worth about $308,000. Finally, Mackenzie Financial Corp bought a new position in shares of Scholar Rock in the 4th quarter worth about $221,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).